Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 8/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.71 |
| ▸ | PRKCG | P05129 | 2/20 | 0.71 |
| ▸ | PRKCB | P05771 | 2/20 | 0.71 |
| ▸ | PRKCH | P24723 | 2/20 | 0.71 |
| ▸ | PRKCI | P41743 | 2/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.71 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.71 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.71 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 17/20 | 0.71 |
| ▸ | BCR | P11274 | 17/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.71 |
| ▸ | SRC | P12931 | 4/20 | 0.71 |
| ▸ | EGFR | P00533 | 2/20 | 0.65 |
| ▸ | ABL2 | P42684 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903186 | 0.89 | ABL1 (0.75) | PRKCAPRKCDPRKD3PRKCGPRKCB | |
| SCHEMBL4895700 | 0.86 | ABL1 (0.75) | PRKCAPRKCDPRKD3PRKCGPRKCB | |
| SCHEMBL6980016 | 0.86 | PLK1 (0.69) | PRKCAPRKCDPRKD3PRKCGPRKCB | |
| SCHEMBL4901012 | 0.85 | PRKCA (0.74) | PRKCAPRKCDPRKD3PRKCGPRKCB | |
| SCHEMBL6976605 | 0.84 | ZAP70 (1.00) | PRKCAPRKCDPRKD3PRKCGPRKCB | |
| SCHEMBL1522 | 0.83 | ABL1 (1.00) | PRKCAPRKCDPRKD3PRKCGPRKCB | |
| SCHEMBL4897378 | 0.82 | ABL1 (0.64) | PRKCAPRKCDPRKD3PRKCGPRKCB | |
| SCHEMBL4002022 | 0.82 | PRKCA (0.58) | PRKCAPRKCDPRKD3PRKCGPRKCB | |
| SCHEMBL4903101 | 0.81 | ABL1 (0.59) | PRKCAPRKCDPRKD3PRKCGPRKCB | |
| SCHEMBL4900131 | 0.81 | PDGFRA (0.77) | PRKCAABL1BCRPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605766-A | Pyrimidine derivatives and they are as the purposes of kinase inhibitor | CGI PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | claimed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | claimed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| CN-101605766-A | Pyrimidine derivatives and they are as the purposes of kinase inhibitor | CGI PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-0862560-B1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-6235746-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATIVE AGENT | CELLTECH THERAPEUTICS, LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-5958935-A | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, TK1 | PRKCA 986/4885PRKCD 1111/4885PRKD3 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.